Treatment ‘saves lives’
The controversy over the use of Hydroxychloroquine to combat the Wuhan virus is quite simple to explain. It is proving highly effective in the US and is saving thousands of lives, especially when taken early in the progress of the disease. But it is cheap and will not make a lot of money for the drug company manufacturing it.
One of the authors of the Veterans Affairs study that claimed the drug had no effect on the recovery of patients stricken by the virus was receiving grants of up to $250,000 from Gilead Sciences, a company that has high hopes for their Remdesivir, a not-yet-FDA-approved drug.This will cost $US1000 a dose.
The V.A. study was based on end-stage patients with severe co-morbidities and with little chance of survival.
More than 700 doctors have joined Republican Senator Ron Johnson in writing to President Trump asking him to make Hydroxychloroquine more widely available. Were I to have the misfortune to come down with the Wuhan virus myself, I would insist on early treatment with appropriate doses of Hydroxychloroquine. It saves lives!